

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2762	ACE adj inhibitor	US-PGPUB; USPAT; EPO; JPO; DERWENT	ADJ	OFF	2006/11/17 10:09
S2	2110	calcium adj antagonist	US-PGPUB; USPAT; EPO; JPO; DERWENT	ADJ	OFF	2006/11/17 10:09
S3	92	S1 same S2	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	OFF	2006/11/17 10:21
S4	3748	lisinopril	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/17 10:21
S5	315	lercanidipine	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/17 10:22
S6	61	S4 with S5	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/17 10:58
S7	77	S4 same S5	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	ON	2006/11/17 10:32
S8	2	"20030180355"	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/17 10:58
S9	284	S1 and S4	USPAT	AND	OFF	2006/11/17 11:56
S10	20672	hypertension	USPAT	AND	OFF	2006/11/17 11:57
S11	229	S9 and S10	USPAT	AND	OFF	2006/11/17 13:36
S12	214	"4046889"	USPAT	AND	OFF	2006/11/17 12:05
S13	294	"4374829"	USPAT	AND	OFF	2006/11/17 12:05
S14	2	"4968832"	USPAT	AND	OFF	2006/11/17 13:36

OTHER CA INDEX NAMES:

CN L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, (S)-

OTHER NAMES:

CN	Acerbon
CN	Alapril
CN	Carace
CN	Cipral
CN	Cipril
CN	Coric
CN	Inopril
CN	Linopril
CN	Linvas
CN	Lipril
CN	Lisinopril
CN	Lisipril
CN	Lisoril
CN	Lispril
CN	Listril
CN	MK 521
CN	MK 522
CN	N- (1(S) -Ca
CN	N2- [(S) -1-
CN	Noperten
CN	Novatec
CN	Presiten
CN	Prinil
CN	Prinivil
CN	Prinivil
CN	Tensopril
CN	Tensyn
CN	Vivatec
CN	Zestril

```
FS STEREOSEARCH
MF C21 H31 N3 O5
CI COM
```


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU,
DRUGU, EMBASE, IFICDB, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMPATENTS,
IMSRESEARCH, IPA, MEDLINE, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS,
RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL,
VETU

```
(*File contains numerically searchable property data)
```

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1530 REFERENCES IN FILE CA (1907 TO DATE)


36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1535 REFERENCES IN FILE CAPLUS (1907 TO DATE).

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 100427-26-7 REGISTRY
ED Entered STN: 22 Feb 1986
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-
, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN Lercanidipine
CN Masnidipine
CN Zanidip
MF C36 H41 N3 O6
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC,
PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

170 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
170 REFERENCES IN FILE CAPLUS (1907 TO DATE)

FILE 'HOME' ENTERED AT 10:46:08 ON 17 NOV 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:46:46 ON 17 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2006 HIGHEST RN 913474-36-9

DICTIONARY FILE UPDATES: 16 NOV 2006 HIGHEST RN 913474-36-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "LISINOPRIL"/CN 25

E1	1	LISINCICLINA/CN
E2	1	LISINO/CN
E3	1 -->	LISINOPRIL/CN
E4	1	LISINOPRIL DIHYDRATE/CN
E5	1	LISINOPRIL MONOHYDRATE/CN
E6	1	LISINOPRIL-HCTZ MIXT./CN
E7	1	LISINOPRIL-HYDROCHLOROTHIAZIDE MIXT./CN
E8	1	LISINOPRIL-KETANSERIN MIXT./CN
E9	1	LISIPRIL/CN
E10	1	LISIPROFEN/CN
E11	1	LISITSYNITE/CN
E12	1	LISITSYNITE (K(BSI206))/CN
E13	1	LISIUM/CN
E14	1	LISKANTIN/CN
E15	1	LISKEARDITE/CN
E16	1	LISKONUM/CN
E17	1	LISN/CN
E18	1	LISOFYLLINE/CN
E19	1	LISOLIPIN/CN
E20	1	LISOMUCIL/CN
E21	1	LISOPHYLLINE/CN
E22	1	LISORIL/CN
E23	2	LISOZIMA/CN
E24	1	LISPAMINA/CN
E25	1	LISPAMOL/CN

=> S E3

L1 1 LISINOPRIL/CN

=> DIS L1 1 IDE

THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 76547-98-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, (S)-

OTHER NAMES:

CN Acerbon

CN Alapril

CN Carace

CN Cipral

CN Cipril

CN Coric

CN Inopril

CN Linopril

CN Linvas

CN Lipril

CN Lisinopril

CN Lisipril

CN Lisoril

CN Lispril

CN Listril

CN MK 521

CN MK 522

CN N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline

CN N2-[(S)-1-Carboxy-3-phenylpropyl]-L-lysyl-L-proline

CN Noperten

CN Novatec

CN Presiten

CN Prinil

CN Prinivil

CN Prinvil

CN Tensopril

CN Tensyn

CN Vivatec

CN Zestril

FS STEREOSEARCH

MF C21 H31 N3 O5

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DRUGU, EMBASE, IFICDB, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1530 REFERENCES IN FILE CA (1907 TO DATE)

36 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1535 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "LERCANIDIPINE"/CN 25

E1	1	LERCADIP/CN
E2	1	LERCAN/CN
E3	1	--> LERCANIDIPINE/CN
E4	1	LERCANIDIPINE HYDROCHLORIDE/CN
E5	1	LERCAPIN/CN
E6	1	LERCATON/CN
E7	1	LERCHEINE BROMIDE/CN
E8	1	LERCHEINE CHLORIDE/CN
E9	1	LERDELIMUMAB/CN
E10	1	LERENOX/CN
E11	1	LEREPO4 PROTEIN (HUMAN CLONE MGC:31837 IMAGE:5020890)/CN
E12	1	LERF 37/CN
E13	1	LERGEFIN/CN
E14	1	LERGIGAN/CN
E15	1	LERGINE/CN
E16	1	LERGINE CHLORIDE/CN
E17	1	LERGITIN/CN
E18	1	LERGO/CN
E19	1	LERGOBAN/CN
E20	1	LERGOBINE/CN
E21	1	LERGOBIT/CN
E22	1	LERGOPENIN/CN
E23	1	LERGOTRIL/CN
E24	1	LERGOTRILE/CN
E25	1	LERGOTRILE MESYLATE/CN

=> S E3

L2 1 LERCANIDIPINE/CN

=> DIS L2 1 IDE

THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 100427-26-7 REGISTRY


ED Entered STN: 22 Feb 1986

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-
, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN Lercanidipine

CN Masnidipine
 CN Zanidip
 MF C36 H41 N3 O6
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE,
 IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC,
 PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

170 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 170 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
14.64	14.85

FILE 'CAPLUS' ENTERED AT 10:48:40 ON 17 NOV 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Nov 2006 VOL 145 ISS 22
 FILE LAST UPDATED: 16 Nov 2006 (20061116/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 76547-98-3
 REG1STRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4 1535 L3

=> s 100427-26-7

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6 170 L5

=> l4(s)l6

L4(S)L6 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l4(s)l6

L7 0 L4(S)L6

=> s l4(p)l6

L8 0 L4(P)L6

=> s l4 and l6

L9 19 L4 AND L6

=> d ti au abs so py 1-19

L9 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

IN Cedarbaum, Jesse; Holash, Jocelyn

AB The invention is related to therapeutic methods of treating diseases in a mammal with a vascular endothelial growth factor (VEGF) antagonist in combination with one or more antihypertensive agents. The VEGF antagonist is a dimeric fusion protein capable of binding VEGF with a high affinity composed of two receptor-Fc fusion protein consisting of the principal ligand-binding portions of the human VEGFR1 and VEGFR2 receptor extracellular domains fused to the Fc portion of human IgG1 (termed a "VEGF trap"). More specifically, the VEGF antagonist is a dimer composed of two fusion proteins each having an Ig-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. The combined therapeutics of the invention achieves maximal anti-angiogenic activity while minimizing the known side effects resulting from treatment with anti-angiogenic agents, specifically, hypertension. The combination of an anti-angiogenic agent with an ACE inhibitor or angiotensin receptor blocker may also be used to prevent proteinuria in subjects at risk thereof.

SO PCT Int. Appl., 20pp.

CODEN: PIXXD2

PY 2006

2006

- L9 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel dosage form comprising modified-release and immediate-release active ingredients
IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.
SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
PY 2006
2004
2004
- L9 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching
AU Mueller, C. A.; Weinmann, W.; Dresen, S.; Schreiber, A.; Gergov, M.
AB A new multi-target screening (MTS) procedure for drugs in blood and urine for toxicol. anal. has been developed using a hybrid triple-quadrupole linear ion trap mass spectrometer (QTrap) for the fast detection and identification of 301 forensically important drugs, e.g. tranquilizers (benzodiazepines), hypnotics, drugs of abuse (opiates, cocaine, amphetamines, cannabinoids), antidepressants, neuroleptics, and some cardiac drugs, in one single liquid chromatog./tandem mass spectrometry (LC/MS/MS) anal. Samples were extracted either with liquid-liquid extraction or solid-phase extraction. A multiple reaction monitoring (MRM) as survey scan and an enhanced product ion (EPI) scan as dependent scan were performed in an information-dependent acquisition (IDA) experiment. Finally, drug identification was carried out by library search with a newly developed MS/MS library based on EPI spectra at three different collision energies in pos. mode. The advantage of this newly developed method is the possibility to detect and identify 301 drugs in one single LC/MS/MS run.
SO Rapid Communications in Mass Spectrometry (2005), 19(10), 1332-1338
CODEN: RCMSEF; ISSN: 0951-4198
PY 2005
- L9 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Lisinopril/lercanidipine combination therapy
IN Leonardi, Amedeo; Sartani, Abraham; Sironi, Giorgio
AB Disclosed are compns. and methods for treating hypertension comprising lisinopril and lercanidipine and optionally including a diuretic in amts. effective in combination to reduce blood pressure to a patent in need of treatment.
SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U. S. Ser. No. 688,061.
CODEN: USXXCO
PY 2005
2004
- L9 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
IN Fong, Benson M.; Cornett, Glen V.
AB Preferred embodiments of the invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.

More particularly, aspects of the invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

PY 2005

2005

2006

L9 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Combination therapy for the treatment of dyslipidemia

IN Erundu, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg, Leonardus H. T.

AB The invention relates to compns. comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The invention further provides pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2

PY 2005

2005

2006

2006

L9 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Combination therapy for the treatment of diabetes

IN Erundu, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg, Leonardus H. T.; Kanatani, Akio

AB The present invention relates to compns. comprising an anti-obesity agent and an anti-diabetic agent useful for the treatment of diabetes, diabetes associated with obesity and diabetes-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2

PY 2004

2005

2006

L9 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Combination therapy using an 11 β -hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders

IN Kampen, Gita Camilla Tejlgaard; Andersen, Henrik Sune

AB The invention discloses combination therapy comprising the administration of an 11 β -hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

SO PCT Int. Appl., 297 pp.

CODEN: PIXXD2

PY 2004

2005

2006

2006

2006

L9 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Oral drug delivery systems with immediate dissolution and release that mask the unpleasant taste of the active substance and method for their preparation

IN Petereit, Hans-Ulrich; Meier, Christian; Gryczke, Andreas

AB The invention concerns oral drug delivery systems with immediate dissoln. and release that mask the unpleasant taste of the active substance and that are prepared by intense mixing of (a) an anionic drug; (b) a copolymer of acrylic acid or methacrylic acid C1-C4 esters with (meth)acrylate monomers containing tertiary amino-groups; (c) 5-50 weight/weight% rel. to (b) C12-C22 carboxylic acid; the mixture is melted, mixed, kneaded, cooled and ground to 200 µm size powder particles. The powder is embedded into a water-soluble matrix with other pharmaceutical auxiliary components in a way that the amount of emulsifiers with HLB ≥ 14 does not exceed 3 weight/weight% in relation to the copolymer. Mixing is performed in twin-screw extruders at 80-200 °C; pressing, casting, granulation or freeze drying is used for embedding. Thus a composition was prepared from (g):

Eudragit

E PO 39.42; stearic acid 35.2; ibuprofen 16.9; talc 8.4. The mixture was kneaded at 100°C for 20 min; 1 g of the cooled composition was tasted; after 2 min no bitterness was sensed.

SO Ger. Offen., 9 pp.

CODEN: GWXXBX

PY 2004

2004

2004

2004

2005

2005

2006

2006

L9 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Nitrosated compounds in methods of treating vascular diseases characterized by nitric oxide insufficiency

IN Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.; Worcel, Manuel

AB The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress. Nitric oxide action was shown to be impaired in the microvasculature of black hypertensive patients to a greater extent than in white hypertensive patients.

SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 679,257.

CODEN: USXXCO

PY 2004

2003
2004

- L9 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Lisinopril/lercanidipine combination for the treatment of hypertension
IN Sartani, Abraham; Leonardi, Amedeo; Sironi, Giorgio
AB Pharmaceutical compns. for the treatment of hypertension, comprising a lisinopril/lercanidipine combination, suitable to decrease blood pressure and maintaining min. side effects, are described. A tablet contained lercanidipine hydrochloride 10, lisinopril (as dihydrate) 10, lactose 102, microcryst. cellulose 40, sodium bicarbonate 8, sodium starch glycolate 20, povidone K30 8, and magnesium stearate 2 mg. Coating of the tablet comprised hypromellose 1.91, talc 0.15, titanium dioxide 0.60, Macrogol-6000 0.30, and ferric oxide 0.04 mg. Combination treatment with lisinopril and lercanidipine lead to significantly greater decreases in both systolic blood pressure and diastolic blood pressure in rats as compared to vehicle or lisinopril or lercanidipine alone.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
PY 2004
2004
2005
2006
- L9 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of cholesteryl ester transfer protein (CETP) inhibitors and antihypertensive agents and optional HMG-CoA reductase inhibitors for the treatment of cardiovascular conditions
IN Ruggeri, Roger Benjamin
AB The invention discloses pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof, and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, kits containing such combinations, and methods of using such combinations to treat subjects suffering from atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female).
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
PY 2004
2004
2006
2004
2004
2005
2005
2005
2005
2006
- L9 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
IN Krul, Elaine S.
AB Methods for treating or preventing one or more cardiovascular conditions in a subject comprises treating the subject with a therapeutically effective amount of a selective cyclooxygenase-1 inhibitor or a pharmaceutically-acceptable salt, tautomer or prodrug thereof alone or in combination with either a drug used in the treatment or prevention of a

cardiovascular condition or a non-drug therapy used in the treatment of a cardiovascular condition. Cyclooxygenase-1 inhibitor, 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole (I), was prepared from 4'-chloroacetophenone and (4-methoxyphenyl)hydrazine hydrochloride. I inhibited development of atherosclerosis in cholesterol-fed apoE knockout mice.

SO U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

PY 2003

L9 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI In vivo delivery methods and compositions

IN Kensey, Kenneth

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least 1 drug. Agents effective to regulate at least 1 of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 819,924.

CODEN: USXXCO

PY 2003

2000

1999

2001

2001

2001

2001

2001

2000

2002

2002

2003

2002

2002

2003

2002

2003

2002

2003

L9 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Buccal sprays or capsules containing cardiovascular or renal drugs

IN Dugger, Harry A., III

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a polar lingual spray contained isoproterenol-HCl 0.5-6, water 50-75, EtOH 5-10, PEG 5-15, sorbitol 0.4-1.0, aspartame 0.04-0.1, and flavors 2-3%.

SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.

CODEN: USXXCO

PY 2003

1999
2000
2000
2004
2004
2004
2004
2005
2006
2005

- L9 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Discrimination and selection of new potential antibacterial compounds using simple topological descriptors
AU Murcia-Soler, Miguel; Perez-Gimenez, Facundo; Garcia-March, Francisco J.; Salabert-Salvador, M. Teresa; Diaz-Villanueva, Wladimiro; Medina-Casamayor, Piedad
AB The aim of the work was to discriminate between antibacterial and non-antibacterial drugs by topol. methods and to select new potential antibacterial agents from among new structures. The method used for antibacterial activity selection was a linear discriminant anal. (LDA). It is possible to obtain a QSAR interpretation of the information contained in the discriminant function. We make use of the pharmacol. distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new antibacterial agents.
SO Journal of Molecular Graphics & Modelling (2003), 21(5), 375-390
CODEN: JMGMFI; ISSN: 1093-3263
PY 2003
- L9 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and apparatus for determining and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment
IN Kensey, Kenneth; Hokanson, Charles
AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
PY 2002
2003
1999
2001
2001
2001
2000
2002
2003
2002
- L9 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods for in vivo drug delivery based on monitoring blood flow parameters
IN Kensey, Kenneth R.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 727,950.
CODEN: USXXCO

PY 2002
2000
1999
2001
2001
2001
2001
2001
2000
2002
2002
2002
2003
2002
2002
2003
2002
2003
2002
2003
2002
2003

L9 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

TI Methods for drug administration and distribution based on monitoring blood viscosity and other parameters for diagnostics and treatment

IN Kensey, Kenneth

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being, i.e., a human, over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream. For example, when blood viscosity is a blood flow parameter monitored, an agent is selected from i.v. diluents, red blood cell deformability agents, antiurea agents, oral contraceptives, antidiabetic agents, antiarrhythmics, antihypertensives, antihyperlipidemics, antiplatelet agents, appetite suppressants, antiobesity agents, blood modifiers, smoking deterrent agents, and nutritional supplements.

SO U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO

PY 2002
2000
1999
2001

2001
2001
2001
2001
2000
2002
2002
2003
2002
2003
2002
2003

=> s ACE(w)inhibitor or angiotensin(w)converting(w)enzyme(w)inhibitor

17536 ACE
270 ACES
17758 ACE
(ACE OR ACES)
523209 INHIBITOR
529549 INHIBITORS
825203 INHIBITOR
(INHIBITOR OR INHIBITORS)
8360 ACE(W) INHIBITOR
61256 ANGIOTENSIN
1734 ANGIOTENSINS
61346 ANGIOTENSIN
(ANGIOTENSIN OR ANGIOTENSINS)
71779 CONVERTING
2 CONVERTINGS
71780 CONVERTING
(CONVERTING OR CONVERTINGS)
790073 ENZYME
457845 ENZYMES
1000837 ENZYME
(ENZYME OR ENZYMES)
523209 INHIBITOR
529549 INHIBITORS
825203 INHIBITOR
(INHIBITOR OR INHIBITORS)
9455 ANGIOTENSIN(W) CONVERTING(W) ENZYME(W) INHIBITOR
L10 14124 ACE(W) INHIBITOR OR ANGIOTENSIN(W) CONVERTING(W) ENZYME(W) INHIBITOR

=> s calcium(w)antagonist

788681 CALCIUM
37 CALCIUMS
788684 CALCIUM
(CALCIUM OR CALCIUMS)
164713 ANTAGONIST
120962 ANTAGONISTS
222316 ANTAGONIST
(ANTAGONIST OR ANTAGONISTS)
L11 7894 CALCIUM(W) ANTAGONIST

=> s l10(p) l11

L12 541 L10(P) L11

=> s l10(s) l11

L13 446 L10(S) L11

=>